Document is current
Any future updates will be listed below
-
Authors
Chabanon, Roman M. https://orcid.org/0000-0001-5417-3060
Shcherbakova, Liudmila https://orcid.org/0000-0001-7336-9974
Lacroix-Triki, Magali https://orcid.org/0000-0002-6641-8536
Aglave, Marine https://orcid.org/0000-0003-3109-8904
Zeghondy, Jean https://orcid.org/0000-0001-8811-4085
Kriaa, Victor https://orcid.org/0009-0007-3643-2488
Gougé, Antoine https://orcid.org/0009-0001-6996-2246
Garrido, Marlène
Edmond, Elodie
Bigot, Ludovic
Krastev, Dragomir B. https://orcid.org/0000-0003-4298-7272
Brough, Rachel
Pettitt, Stephen J. https://orcid.org/0000-0003-3313-3857
Thomas-Bonafos, Thibault
Samstein, Robert https://orcid.org/0000-0001-6860-2401
Massard, Christophe
Deloger, Marc https://orcid.org/0000-0002-6352-101X
Tutt, Andrew NJ https://orcid.org/0000-0001-8715-2901
Barlesi, Fabrice https://orcid.org/0000-0001-5793-3539
Loriot, Yohann https://orcid.org/0000-0002-8338-1739
Delaloge, Suzette https://orcid.org/0000-0003-2106-9165
Tawk, Marcel https://orcid.org/0000-0003-4267-4743
Degerny, Cindy https://orcid.org/0000-0002-9810-3627
Lin, Yea-Lih https://orcid.org/0000-0003-4063-0771
Pistilli, Barbara https://orcid.org/0000-0002-9184-7199
Pasero, Philippe https://orcid.org/0000-0001-5891-0822
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Postel-Vinay, Sophie https://orcid.org/0000-0001-5562-1857
- License Information
-
More Information
Article History
Received: 4 December 2024
Accepted: 2 July 2025
First Online: 29 July 2025
Competing interests
: R.M.C. makes the following disclosures: is named inventor on a patent describing the use of ADAR1 inhibitors as anti-cancer agents (WO/2024/189433). J.Z. makes the following disclosures: has received research funding and travel subsidies from Menarini. B.P. makes the following disclosures: has received research funding as part of an institutional program from: Astra Zeneca, Daiichi Sankyo, Gilead, Seagen, MSD; receives and/or has received consulting fees from: Astra Zeneca (institutional), Seagen (institutional), Gilead (institutional), Novartis (institutional), Lilly (institutional), MSD (institutional), Pierre Fabre (personal), Daiichi Sankyo (institutional/personal), Olema (institutional); has received travel subsidies from: Astra Zeneca; Pierre Fabre; MSD; Daiichi Sankyo, Pfizer. A.N.J.T. makes the following disclosures: Receipt of grants / research support: AstraZeneca research costs associated with OlympiA, Myriad Genetics research support for TNT Trial, Breast Cancer Now research grant to Institution, CRUK research grant to Institution. Receipt of honoraria or consultation fees: AstraZeneca, Inbiomotion, Gilead, Innovation in Breast Cancer Symposium, SABCS, GBCC, Cancer Panel, Research to Practise, AACR, Aicme, Penn Medicine, PAGE Therapeutics, Ellipses, VHIO, Dana Faber David Livingston Memorial Symposium, Tango Therapuetics, Guardant, CRUK, Neogenomics, Merck. Educational seminar: Guardant. Stock option: InBioMotion. Royalties: Benefits from ICR’s Inventors Scheme associated with patents for use of several PARP inhibitors in DNA repair-deficient cancers held by AstraZeneca with royalty payments to A.N.J.T.’s personal account and research accounts at the Institute of Cancer Research, and to the Institute of Cancer Research. Institutional financial interests: Royalties as above from AstraZeneca. Research costs from AstraZeneca, Myriad Genetics. Non-financial interests: Leadership/Guideline Advisor roles: Director of Breast Cancer Now Research Centre—ICR/KCL, St Gallen Early Breast Cancer Guidelines Panel, ESMO Early Breast Cancer Guidelines Committee, ESMO Scientific Committee, Chair—CRUK Clinical Research Committee, BCRF SAB member, Strategy Committee UK NCRI, Trustee The Cridlan Ross Smith Charitable Trust. C.J.L. makes the following disclosures: receives and/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore; has received consultancy, SAB membership or honoraria payments from: FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, ForEx; has stock in: Tango, Ovibio, Hysplex, Tesselate, Ariceum. C.J.L. is also named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR “Rewards to Inventors” scheme and also reports benefits from this scheme associated with patents for PARP inhibitors paid into C.J.L.’s personal accounts and research accounts at the Institute of Cancer Research. C.J.L. is also named inventor on a patent describing the use of ADAR1 inhibitors as anti-cancer agents (WO 2024/189433 A1). S.P.V. makes the following disclosures: has received research funding from Hoffman La Roche and AstraZeneca for unrelated research projects. As part of the Drug Development Department (DITEP), S.P.V. is principal investigator or sub-investigator of clinical trials from Abbvie, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly, Exelixis, Forma, Gamamabs, Genentech, Inc., GlaxoSmithKline, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharm. Dev., Inc., Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro Inc, and Xencor. S.P.V. has participated to advisory boards for Merck KGaA. S.P.V. is also named inventor on a patent describing the use of ADAR1 inhibitors as anti-cancer agents (WO 2024/189433 A1). All other authors have no conflicts of interest or financial interests to disclose.
